• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Discovery of novel acylhydrazone neuraminidase inhibitors

tetano

Editor, Senior Moderator
Eur J Med Chem. 2019 Apr 5;173:305-313. doi: 10.1016/j.ejmech.2019.04.006. [Epub ahead of print]
[h=1]Discovery of novel acylhydrazone neuraminidase inhibitors.[/h] Zhao ZX[SUP]1[/SUP], Cheng LP[SUP]2[/SUP], Li M[SUP]1[/SUP], Pang W[SUP]3[/SUP], Wu FH[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Neuraminidase (NA) plays a crucial role in the replication and transmission of influenza virus. NA inhibitors have been developed as effective treatments for influenza A and B infections. In this paper, a new lead neuraminidase inhibitor 6a (IC[SUB]50[/SUB] = 7.10 ? 0.2 μM) was discovered by ligand-based virtual screening, receptor-based virtual screening, molecular dynamics simulation (MD), and bioassay validation. MD simulation indicates that the morpholinyl group of 6a could be embedded in 430-loop of NA. To exploit the 430-loop in the active site, a series of novel acylhydrazone NA inhibitors 6b-6g were designed and synthesized based on the lead compound 6a. Compound 6e exerts the most potency, with IC[SUB]50[/SUB] value of 2.37 ? 0.5 μM against NA, which is lower than that of oseltamivir carboxylate (OC) (IC[SUB]50[/SUB] = 3.84 μM). Overall, this work provided unique insights in the discovery of potent inhibitors against NA.
Copyright ? 2019 Elsevier Masson SAS. All rights reserved.


[h=4]KEYWORDS:[/h] 430-Loop; Acylhydrazone; Neuraminidase inhibitor; Virtual screening

PMID: 31022584 DOI: 10.1016/j.ejmech.2019.04.006
 
Back
Top Bottom